Cyclosporine A or Intravenous Cyclophosphamide for Lupus Nephritis: The Cyclofa-Lune Study
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
Intravenous cyclophosphamide is considered to be the standard of care for treatment of
proliferative lupus nephritis. However, its use is limited by potentially severe toxic
effects. Cyclosporine A has been suggested to be an efficient and safe treatment alternative
to cyclophosphamide. In a randomized, multicenter, open-label, controlled trial the
investigators sought to compare the efficacy of oral cyclosporine A with intravenous pulse
cyclophosphamide to induce durable remission in patients with lupus nephritis III-IV.
Phase:
Phase 2
Details
Lead Sponsor:
Institute of Rheumatology, Prague
Collaborators:
Charles University, Czech Republic Department of Rheumatology, Hospital, Ceske Budejovice, Czech Republic Ministry of Health, Czech Republic National Institute of Rheumatology, Piestany, Slovakia Palacky University St. Anna Hospital, Brno, Czech